A petition urges the FDA to allow certain radiology AI software updates via postmarket study requirements instead of new 510(k) applications.
Key Details
- 1Petition submitted to the FDA seeks a streamlined pathway for radiology AI software with prior 510(k) clearance.
- 2Proposal targets CADx, CADe/x, CADt, and medical image analyzer software types under specified FDA regulations.
- 3Vendors with cleared devices could forgo new 510(k) submissions for new features, provided robust postmarket measures are in place.
- 4Existing 510(k) pathway would remain as an option; the new pathway would be partially exempt under defined conditions.
- 5FDA is accepting comments on the proposal until February 27, 2026.
- 6The proposal aims to close the 'innovation gap' between the U.S. and other regions, citing more limited AI diagnostic offerings in the U.S.
Why It Matters
If adopted, this pathway could accelerate the deployment of AI innovations in U.S. radiology by reducing regulatory redundancy, addressing concerns about lagging AI adoption compared to Europe. It signals ongoing regulatory evolution in medical imaging AI oversight.
Source
AuntMinnie
Related News
•Radiology Business
ACR Approves New Framework for Assessing Imaging AI in Practice
The American College of Radiology Council has approved a new practice parameter to guide the assessment and deployment of AI in imaging.
•AuntMinnie
AI in Radiology: Augmentation, Not Replacement – Risks and Realities Reviewed
AI is reshaping radiology workflows but is not ready to replace radiologists, as judgment, accountability, and clinical complexity remain unmet by current technology.
•Radiology Business
NCCN Endorses AI Risk Tools for Breast Cancer Screening
NCCN's 2026 guidelines recommend routine integration of AI-based 5-year breast cancer risk prediction from mammograms.